To include your compound in the COVID-19 Resource Center, submit it here.

Cancer

INDICATION: Non-small cell lung cancer (NSCLC)

In vitro, cell culture and mouse studies identified a piperazine-based dual MDM2/HDAC6 inhibitor that could help treat NSCLC.

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE